Related Experiment Video
Updated: Oct 18, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Abstract:
In the phase III IMpower-010 trial, patients with non-small cell lung cancer whose disease returned after surgery and adjuvant chemotherapy received a year of adjuvant therapy with the immune checkpoint inhibitor atezolizumab. Use of this drug was associated with a 34% reduction in the risk of disease progression compared with best supportive care among patients whose tumors expressed PD-L1. The benefit was even greater in patients with PD-L1 expression of at least 50%.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Cancer Survival Analysis

